– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –MELBOURNE, AUSTRALIA and SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE)…
Partnership will expand Plus’ capability to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda and reinforce supply chain…
Conference call and webcast to begin at 8:00 AM ETBEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc.…
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025;…
NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Research Grid, the AI startup that helps medical research institutions automate back-office admin for…
MINNEAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of clinically relevant spatial biology data.…
LUND, SWEDEN / ACCESSWIRE / November 05, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported preclinical results…
VANCOUVER, BC / ACCESSWIRE / November 4, 2024 / StimCell Energetics Inc. (formerly "Cell MedX Corp.") (OTC PINK:CMXC) ("StimCell", or…
DELRAY BEACH, Fla., Nov. 4, 2024 /PRNewswire/ -- The global AI in pathology market is projected to reach USD 169.8 million…
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studiesCollaboration underscores Lonza's commitment to…